Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NetApp Inc. (NTAP) vs Novartis AG (NVS) Price & Performance

NetApp Inc.Trade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

NetApp Inc. vs Novartis AG — how do they compare? NetApp Inc. trades at $184.74 (market cap $37.15B), while Novartis AG trades at $139.6 (market cap $262.64B). The key difference: Novartis AG is far larger — about 7.1× NetApp Inc.'s market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.

NTAPNVS
Market Cap
$37.15B$262.64B
Sector
TechnologyHealth
52-Week High
$207.08$168.62
52-Week Low
$94.11$121.80
Enterprise Value
$36.11B$303.97B
Dividend Yield
1.1%3.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NetApp Inc.

NetApp (NTAP) trades at $189.13, up 1.91% with strong technical momentum and bullish moving average signals. The company delivered three consecutive earnings beats, with Q1 2026 EPS of $2.58 beating expectations by 21.7%. Revenue growth accelerated to 30% year-over-year in the latest quarter, driven by AI storage demand and cloud momentum. Analyst consensus remains positive with a $193.55 price target, though valuation metrics appear elevated with a P/E of 26.71 and P/S of 5.12.

The outlook remains constructive given strong AI-driven demand and raised 2027 guidance, but premium valuation and margin pressures present risks. Institutional sentiment is mixed with 36.6% buy ratings versus 52.1% hold ratings. Key catalysts include continued AI infrastructure adoption, while risks include execution challenges and competitive pressures in the storage market.

Novartis AG

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About NetApp Inc.

NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.

Read more on NTAP

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS